Highlights

  • Percheron Therapeutics (ASX:PER) completed Manufacturing of a new HMBD-002 drug substance batch.
  • The milestone supports plans to restart clinical development of its VISTA-targeting cancer antibody.
  • HMBD-002 previously completed a Phase I study showing it was generally safe and well tolerated.
  • Funding, trial design and future clinical outcomes remain key factors for the program.

Percheron Therapeutics (ASX:PER) has completed a key manufacturing milestone for HMBD-002, supporting plans to return the company’s lead cancer antibody program into clinical development.

The completed drug substance batch removes a Supply requirement before new clinical studies can begin, allowing Percheron to progress towards its next clinical stage.

However, HMBD-002 remains an early-stage oncology program, with future value dependent on clinical outcomes, funding capacity and regulatory progress.

What Happened?

On 17 June 2026, Percheron Therapeutics announced completion of manufacturing for a new batch of HMBD-002 drug substance.

The material was produced by Hummingbird Bioscience under a licensing agreement established in June 2025 using a recombinant Chinese hamster ovary (CHO) cell expression system.

Percheron reported that the batch passed its Certificate of Analysis, with quality attributes within expected ranges.

The company stated that drug substance delivery occurred in late June 2026, with fill-and-finish packaging expected during Q3'2026.

The company plans to return HMBD-002 to clinical development during the second half of 2026.

Why It Matters

Manufacturing is an important step in clinical development because biologic therapies require controlled production processes before patient dosing can begin.

The completion of a released drug substance batch provides the material required for future clinical studies.

For Percheron, the milestone converts a planned clinical restart into a more defined pathway.

HMBD-002 previously completed a Phase I clinical trial in advanced cancer patients, and the new manufacturing batch supports progression beyond that initial study.

The Numbers

HMBD-002 is a monoclonal antibody targeting VISTA, an immune checkpoint regulator involved in cancer immune responses.

The completed Phase I study evaluated HMBD-002 in 48 patients across six clinical centres in the United States.

The company reported that the treatment was generally safe and well tolerated as both a monotherapy and in combination with Merck’s Keytruda (pembrolizumab).

Percheron reported cash of A$4.05 million at the end of the June 2026 quarter, compared with A$3.10 million three months earlier.

The company raised approximately A$2.2 million through a non-renounceable entitlement offer priced at A$0.005 per share.

HMBD-002 received the provisional international non-proprietary name minperstobart, with final World Health Organization confirmation expected in the second half of 2027.

The Bigger Picture

HMBD-002 is being developed as a VISTA-targeting immunotherapy, an area being investigated as a potential complement to established immune checkpoint inhibitors.

While PD-1 and PD-L1 therapies have changed cancer treatment, some patients do not respond or later develop resistance.

VISTA represents a different immune pathway that researchers are exploring for additional treatment approaches.

Percheron’s previous combination data involving HMBD-002 and Keytruda provides background for further development, although early safety data does not confirm future efficacy.

The company has also conducted research collaborations, including work examining VISTA expression in triple-negative breast cancer.

The Bull Case

The positive case for Percheron Therapeutics (ASX:PER) is based on advancing HMBD-002 back into clinical development with a defined manufacturing pathway.

The company has completed an important supply milestone and established funding support to continue development activities.

The VISTA target provides a differentiated approach within oncology immunotherapy, particularly if combination strategies demonstrate improved outcomes.

Successful clinical results could support future partnerships or additional development opportunities.

Risks Investors Should Understand

Percheron Therapeutics (ASX:PER)’s Business faces risks including clinical trial uncertainty, funding limitations, regulatory delays and concentration around HMBD-002.

The antibody has only completed early-stage clinical testing, and safety results from 48 patients do not demonstrate effectiveness in larger controlled studies.

VISTA remains an emerging therapeutic target with no approved commercial products.

The company’s cash balance remains limited relative to the costs of antibody development, creating potential future funding and dilution risks.

Clinical timelines, manufacturing activities and regulatory processes may also experience delays.

What Comes Next?

The next milestones include completion of HMBD-002 fill-and-finish activities and confirmation of the timing and structure of the next clinical study.

Investors will monitor trial design details, including patient numbers, cancer types and whether future studies evaluate monotherapy or combination approaches.

Further updates on regulatory discussions, funding and clinical progression will remain important.

Conclusion

Percheron Therapeutics (ASX:PER) has completed a necessary manufacturing milestone that supports the planned return of HMBD-002 to clinical development.

The achievement provides the material required for future patient studies and removes one operational hurdle for the program.

However, HMBD-002 remains an early-stage cancer therapy candidate. The long-term opportunity will depend on demonstrating clinical benefit, securing sufficient funding and progressing through future regulatory stages.